Helicobacter Pylori Diagnostic Market Size and Share Report Highlights USD 994.69 Million Valuation by 2031 Backed by Technological Advancements

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Helicobacter Pylori Diagnostic Market Size, Share & Trends Analysis Report By Technology (Immunoassays, POC, Molecular Diagnostics), By End User (Hospitals, Diagnostics Laboratories, Clinics)- Market Outlook And Industry Analysis 2031"

The Global Helicobacter Pylori Diagnostic Market is estimated to reach over USD 994.69 million by 2031, exhibiting a CAGR of 6.31% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1765

Helicobacter pylori (H. pylori) is a Gram-negative, aerobic bacterium commonly found in the human stomach, where it plays a notable role in the gastric microenvironment. Despite its prevalence, this spiral-shaped microorganism is associated with a heightened risk of several gastrointestinal disorders, including gastric cancer, peptic ulcers, and chronic gastritis, due to its ability to colonize the esophagus, stomach lining, and small intestine.

The increasing incidence of stomach ulcers is a major factor expected to drive the growth of the H. pylori diagnostics market. Additionally, the expanding global elderly population, rising adoption of point-of-care diagnostic devices, a growing preference for non-invasive testing methods, and enhanced accessibility to healthcare diagnostics are further supporting market expansion.

List of Prominent Players in the Helicobacter pylori diagnostic Market:
• Abbott
• Agilent Technologies, Inc.
• Alpha Laboratories
• Avanos Medical Devices.
• Biohit Oyj
• Bio-Rad Laboratories
• Cardinal Health, Inc.
• Certest Biotec
• CorisBioconcept SPRL
• EKF Diagnostics
• Epitope Diagnostics
• Exalenz Bioscience Ltd.
• F. Hoffmann-La Roche Ltd
• Gulf Coast Scientific
• Halyard Health, Inc.
• Helena Laboratories Corporation
• HORIBA Europe GmbH
• Medline Industries, Inc.
• Meridian Bioscience, Inc.
• QIAGEN
• Quest Diagnostics
• Quidel Corporation.
• Sekisui Diagnostics
• Takara Bio Inc.
• Thermo Fisher Scientific, Inc.

Market Dynamics:
Drivers-
The key factors driving market growth include the rising demand for personalized antibiotic therapy and the increasing cost-effectiveness of diagnostic procedures. The adoption of pre- and post-treatment monitoring tests is anticipated to grow, fueled by the availability of affordable antibiotics and shorter treatment durations. Additionally, the growing prevalence of Helicobacter pylori infections, the need for early detection of symptoms, and advancements in diagnostic technologies are crucial contributors to the market's expansion.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Challenges:
The expansion of the Helicobacter pylori diagnostics market is projected to face limitations during the forecast period due to a shortage of skilled healthcare professionals and a general lack of awareness regarding the advantages of diagnostic testing, particularly in emerging economies. Moreover, intense pricing competition within the industry is expected to present a notable obstacle to sustained market growth.

Regional Trends:
In the Asia-Pacific region, the demand for H. pylori diagnostic solutions is primarily fueled by the high incidence of infectious diseases. Adoption rates are expected to increase as a result of persistent public health challenges, including insufficient sanitation and underdeveloped healthcare infrastructure, especially in countries such as India. Additionally, regional market growth is likely to be supported by key industry players through the introduction of innovative diagnostic technologies and the establishment of new manufacturing operations over the forecast period.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1765

Recent Developments:
• In Oct 2018, DiaSorin S.p.A. and Meridian Bioscience, Inc. announced a strategic collaboration in which DiaSorin Inc., a subsidiary of DiaSorin S.p.A., and Meridian Bioscience, Inc. will market DiaSorin's FDA-cleared Helicobacter pylori stool antigen test to detect H. pylori for use on its automatic LIAISON platform under the Meridian brand name worldwide. Meridian and DiaSorin will begin partnering on sales and marketing efforts to hospitals and reference labs in the United States as part of this collaboration. In addition to the royalties collected under the prior agreement, Meridian will obtain royalties on sales of the LIAISON H. pylori stool antigen test in the United States and, now, the United Kingdom.

Segmentation of Helicobacter Pylori Diagnostic Market-
By Technology-
• Immunoassays
• POC
• Molecular Diagnostics
By End-User-
• Hospitals
• Diagnostics Laboratories
• Clinics
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/helicobacter-pylori-diagnostic-market/1765

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.